nach oben

European Archives of Psychiatry and Clinical Neuroscience

18.03.2024 | Original Paper

Evolution of the profiles of new psychotropic drug users before and during the COVID-19 crisis: an original longitudinal approach through multichannel sequence analysis using the French health-care database

verfasst von: Marion Istvan, Mélanie Duval, Karl Hodel, Aurélie Aquizerate, Anicet Chaslerie, Pascal Artarit, Edouard-Jules Laforgue, Caroline Victorri-Vigneau

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience

Einloggen, um Zugang zu erhalten

Abstract

The COVID-19 pandemic has had a substantial impact on mental health. An increase in the use of anxiolytic, hypnotic, and antidepressant drugs has been highlighted in France, but with no information at the individual level (trajectories) or concerning patient characteristics. The objective of this study was to describe the profile of new psychotropic drug users since the beginning of the pandemic. We formed two historical cohorts using the Pays-de-la-Loire regional component of the National Health Data System (SNDS): a “COVID-19 crisis cohort” (2020–2021) and a “control cohort” (2018–2019). We analyzed reimbursements for psychotropic medications (anxiolytics, antidepressants, hypnotics, mood stabilizers, and antipsychotics) using a multichannel sequence analysis and performed clustering analysis of sequences. The proportion of new consumers of psychotropic drugs was higher in the COVID-19 crisis cohort (18.0%) than that in the control cohort (16.0%). In the COVID-19 cohort, three clusters of psychotropic drug users were identified, whereas four clusters were identified in the control cohort. A time lag in treatment initiation was observed in the COVID-19 crisis cohort (September) compared with the control cohort (July). This study is one of the first to analyze the profile of psychotropic treatment users during the COVID-19 crisis. Our analysis sheds light on changes in patterns of psychotropic drug use during the COVID-19 pandemic, possibly associated with changes in prescribing conditions and mental health conditions during the crisis. This study also provides an example of the application of an innovative longitudinal analysis methodology in the field of pharmacoepidemiology.

Nur mit Berechtigung zugänglich

COVID-19 Mental Disorders Collaborators (2021) Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet Lond Engl 398:1700–1712. https://doi.org/10.1016/S0140-6736(21)02143-7

Xiong J, Lipsitz O, Nasri F et al (2020) Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord 277:55–64. https://doi.org/10.1016/j.jad.2020.08.001CrossRefPubMedPubMedCentral

Onyeaka H, Anumudu CK, Al-Sharify ZT et al (2021) COVID-19 pandemic: a review of the global lockdown and its far-reaching effects. Sci Prog 104:368504211019854. https://doi.org/10.1177/00368504211019854CrossRefPubMed

Caroppo E, Mazza M, Sannella A et al (2021) Will nothing be the same again?: changes in lifestyle during COVID-19 pandemic and consequences on mental health. Int J Environ Res Public Health 18:8433. https://doi.org/10.3390/ijerph18168433CrossRefPubMedPubMedCentral

Gloster AT, Lamnisos D, Lubenko J et al (2020) Impact of COVID-19 pandemic on mental health: an international study. PLoS ONE 15:e0244809. https://doi.org/10.1371/journal.pone.0244809CrossRefPubMedPubMedCentral

Beck F, Léger D, Fressard L et al (2020) Covid-19 health crisis and lockdown associated with high level of sleep complaints and hypnotic uptake at the population level. J Sleep Res. https://doi.org/10.1111/jsr.13119CrossRefPubMedPubMedCentral

Chan-Chee C, Léon C, Lasbeur L, et al (2020) The mental health of the French facing the COVID-19 crisis: prevalence, evolution and determinants of anxiety disorders during the first two weeks of lockdown (Coviprev study, March 23–25 and March 30–April 1st, 2020). Santé Publique Fr St-Maurice Fr

Sanborn M, Ali MM, Creedon TB (2023) National trends in psychotropic medication prescribing before and during the COVID-19 pandemic. Psychiatry Res 325:115248. https://doi.org/10.1016/j.psychres.2023.115248CrossRefPubMedPubMedCentral

García MLN, Martínez PF, Bretón EF et al (2023) Psychotropic consumption before and during COVID-19 in Asturias. Spain BMC Public Health 23:494. https://doi.org/10.1186/s12889-023-15360-0CrossRefPubMed

10.

Amill-Rosario A, Lee H, Zhang C, dosReis S (2022) Psychotropic prescriptions during the COVID-19 pandemic among U.S. children and adolescents receiving mental health services. J Child Adolesc Psychopharmacol 32:408–414. https://doi.org/10.1089/cap.2022.0037CrossRefPubMed

11.

Tiger M, Wesselhoeft R, Karlsson P et al (2023) Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia. J Affect Disord 323:292–298. https://doi.org/10.1016/j.jad.2022.11.068CrossRefPubMed

12.

Rabeea SA, Merchant HA, Khan MU et al (2021) Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. Daru J Fac Pharm Tehran Univ Med Sci 29:217–221. https://doi.org/10.1007/s40199-021-00390-zCrossRef

13.

ANSM : Agence nationale de sécurité du médicament et des produits de santé (2017) Etat des lieux de la consommation des benzodiazepines—Point d’Information [State of play of benzodiazepine use - Information point]

14.

Scailteux L-M, Droitcourt C, Balusson F et al (2019) French administrative health care database (SNDS): the value of its enrichment. Therapies 74:215–223. https://doi.org/10.1016/j.therap.2018.09.072CrossRef

15.

Bezin J, Duong M, Lassalle R et al (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26:954–962. https://doi.org/10.1002/pds.4233CrossRefPubMed

16.

Latry P, Molimard M, Bégaud B, Martin-Latry K (2010) How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. Eur J Clin Pharmacol 66:743–748. https://doi.org/10.1007/s00228-010-0819-0CrossRefPubMed

17.

Martin-Latry K, Bégaud B (2010) Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 19:256–265. https://doi.org/10.1002/pds.1912CrossRefPubMed

18.

Prada-Ramallal G, Takkouche B, Figueiras A (2019) Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol 19:53. https://doi.org/10.1186/s12874-019-0695-yCrossRefPubMedPubMedCentral

19.

EPI-PHARE (2020) Usage des médicaments de ville en France durant l’épidémie de la Covid-19 - point de situation jusqu’au 22 novembre 2020 - Rapport 5

20.

Vanoli J, Nava CR, Airoldi C et al (2021) Use of state sequence analysis in pharmacoepidemiology: a tutorial. Int J Environ Res Public Health 18:13398. https://doi.org/10.3390/ijerph182413398CrossRefPubMedPubMedCentral

21.

Istvan M, Caillet P, Rousselet M et al (2021) Change in the regulatory framework for zolpidem: what is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study. Br J Clin Pharmacol 87:3310–3319. https://doi.org/10.1111/bcp.14753CrossRefPubMed

22.

Parkin L, Barson D, Zeng J et al (2018) Patterns of use of long-acting bronchodilators in patients with COPD: a nationwide follow-up study of new users in New Zealand: LABA and LAMA patterns of use. Respirology 23:583–592. https://doi.org/10.1111/resp.13235CrossRefPubMed

23.

Leblanc S, Roux J, Tillaut H et al (2021) Disease-modifying therapy usage in patients with multiple sclerosis in France: a 6-year population-based study. Rev Neurol (Paris) 177:1250–1261. https://doi.org/10.1016/j.neurol.2021.04.006CrossRefPubMed

24.

Brodeur S, Vanasse A, Courteau J et al (2022) Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: a state sequence analysis approach. Acta Psychiatr Scand 145:469–480. https://doi.org/10.1111/acps.13411CrossRefPubMed

25.

Brodeur S, Courteau J, Vanasse A et al (2022) Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study. Br J Psychiatry J Ment Sci. https://doi.org/10.1192/bjp.2022.1CrossRef

26.

Gauthier J-A, Widmer ED, Bucher P, Notredame C (2010) Multichannel sequence analysis applied to social science data. Sociol Methodol 40:1–38. https://doi.org/10.1111/j.1467-9531.2010.01227.xCrossRef

27.

Studer M (2013) WeightedCluster library manual. Pract Guide Creat Typol Trajectories Social Sci R. https://doi.org/10.12682/LIVES.2296-1658.2013.24CrossRef

28.

Hubert LJ, Levin JR (1976) A general statistical framework for assessing categorical clustering in free recall. Psychol Bull 83:1072–1080. https://doi.org/10.1037/0033-2909.83.6.1072CrossRef

29.

R Core Team (2020) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/. Accessed 24 Dec 2021

30.

Gabadinho A, Ritschard G, Müller NS, Studer M (2011) Analyzing and visualizing state sequences in R with TraMineR. J Stat Softw 40:1–37. https://doi.org/10.18637/jss.v040.i04CrossRef

31.

Panchal U, Salazar de Pablo G, Franco M et al (2023) The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. Eur Child Adolesc Psychiatry 32:1151–1177. https://doi.org/10.1007/s00787-021-01856-wCrossRefPubMed

32.

Deng J, Zhou F, Hou W et al (2023) Prevalence of mental health symptoms in children and adolescents during the COVID-19 pandemic: a meta-analysis. Ann N Y Acad Sci 1520:53–73. https://doi.org/10.1111/nyas.14947ADSCrossRefPubMed

33.

Viner R, Russell S, Saulle R et al (2022) School closures during social lockdown and mental health, health behaviors, and well-being among children and adolescents during the first COVID-19 wave: a systematic review. JAMA Pediatr 176:400–409. https://doi.org/10.1001/jamapediatrics.2021.5840CrossRefPubMed

34.

Luijten MAJ, van Muilekom MM, Teela L et al (2021) The impact of lockdown during the COVID-19 pandemic on mental and social health of children and adolescents. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 30:2795–2804. https://doi.org/10.1007/s11136-021-02861-xCrossRef

35.

García-Prado A, González P, Rebollo-Sanz YF (2022) Lockdown strictness and mental health effects among older populations in Europe. Econ Hum Biol 45:101116. https://doi.org/10.1016/j.ehb.2022.101116CrossRefPubMed

36.

Prommas P, Lwin KS, Chen YC et al (2023) The impact of social isolation from COVID-19-related public health measures on cognitive function and mental health among older adults: a systematic review and meta-analysis. Ageing Res Rev 85:101839. https://doi.org/10.1016/j.arr.2022.101839CrossRefPubMed

37.

Pignon B, Gourevitch R, Tebeka S et al (2020) Dramatic reduction of psychiatric emergency consultations during lockdown linked to COVID-19 in Paris and suburbs. Psychiatry Clin Neurosci 74:557–559. https://doi.org/10.1111/pcn.13104CrossRefPubMedPubMedCentral

38.

Pham-Scottez A, Silva J, Barruel D et al (2020) Patient flow in the largest French psychiatric emergency centre in the context of the COVID-19 pandemic. Psychiatry Res 291:113205. https://doi.org/10.1016/j.psychres.2020.113205CrossRefPubMedPubMedCentral

39.

Bocher R, Jansen C, Gayet P et al (2020) Responsiveness and sustainability of psychiatric care in France during COVID-19 epidemic. L’Encephale 46:S81–S84. https://doi.org/10.1016/j.encep.2020.05.004CrossRefPubMedPubMedCentral

40.

Salazar de Pablo G, Vaquerizo-Serrano J, Catalan A et al (2020) Impact of coronavirus syndromes on physical and mental health of health care workers: systematic review and meta-analysis. J Affect Disord 275:48–57. https://doi.org/10.1016/j.jad.2020.06.022CrossRefPubMedPubMedCentral

41.

van Hunsel F, Gardarsdottir H, de Boer A, Kant A (2019) Measuring the impact of pharmacovigilance activities, challenging but important. Br J Clin Pharmacol 85:2235–2237. https://doi.org/10.1111/bcp.14042CrossRefPubMedPubMedCentral

42.

Goedecke T, Morales DR, Pacurariu A, Kurz X (2018) Measuring the impact of medicines regulatory interventions—systematic review and methodological considerations. Br J Clin Pharmacol 84:419–433. https://doi.org/10.1111/bcp.13469CrossRefPubMed

43.

Nguena Nguefack HL, Pagé MG, Katz J et al (2020) Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches. Clin Epidemiol 12:1205–1222. https://doi.org/10.2147/CLEP.S265287CrossRefPubMedPubMedCentral

44.

Gaudart J, Landier J, Huiart L et al (2021) Factors associated with the spatial heterogeneity of the first wave of COVID-19 in France: a nationwide geo-epidemiological study. Lancet Public Health 6:e222–e231. https://doi.org/10.1016/S2468-2667(21)00006-2CrossRefPubMedPubMedCentral

45.

Muller J, Tran Ba Loc P, Binder Foucard F et al (2022) Major interregional differences in France of COVID-19 hospitalization and mortality from January to June 2020. Rev Epidemiol Sante Publique S0398–7620(22):00737–00744. https://doi.org/10.1016/j.respe.2022.08.008CrossRef

Titel: Evolution of the profiles of new psychotropic drug users before and during the COVID-19 crisis: an original longitudinal approach through multichannel sequence analysis using the French health-care database
verfasst von: Marion Istvan
Mélanie Duval
Karl Hodel
Aurélie Aquizerate
Anicet Chaslerie
Pascal Artarit
Edouard-Jules Laforgue
Caroline Victorri-Vigneau
Publikationsdatum: 18.03.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-024-01774-3

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen